Last updated on Thursday, 20 April 2017

Southwest Gynecologic Oncology Associates

Trial #TypeStudy StatusStatus DateTitle
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2017-02-01NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0213GYN Ovarian AdvancedOpen Active2009-09-01GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
INST CR1303GYN Ovarian AdvancedOpen Active2013-07-30(IRB EXEMPT) INST CR1303: Magnesium Levels in Ovarian Cancer Patients Undergoing Taxol and Platinum Based Chemotherapy and the Correlation with Neuropsychologic Outcomes via FACT Quality of Life Scores
UNM 1419GYN Ovarian AdvancedOpen Active2017-03-14INST 1419: A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers with Advanced or Recurrent Ovarian Cancer
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG 0277GYN Uterine AdvancedOpen Active2013-04-16GOG 0277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC#
628503) Followed BY Doxorubicin (NSC# 123127) versus Observation for Uterus-limited,
High-grade Uterine Leiomyosarcoma
SWOG S1404Skin Melanoma AdvancedOpen Active2017-03-01SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
NRG Oncology NRG-GY002GYN Cervical AdvancedOpen Active2016-05-03NRG Oncology NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
GOG 0274GYN Cervical AdvancedOpen Active2012-07-30GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
GOG-0286BGYN Endometrial AdvancedOpen Active2017-01-10GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NRG Oncology NRG-GY008GYN Endometrial AdvancedOpen Active2017-03-10NRG Oncology NRG-GY008: A Phase II Evaluation of Copanlisib (BAY 80-6946) (Ind #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
NRG Oncology NRG-GY005GYN OtherOpen Active2017-01-26NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Pharm M13-694 - GOG-3005GYN OtherOpen Active2016-12-12AbbVie M13-694/GOG-3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG-0281GYN Ovarian AdjuvantOpen Active2016-10-05GOG-0281: A Randomized Phase II/III Study To Assess The Efficacy Of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer